CY1126144T1 - Ετεροαρωματικοι ρυθμιστες υποδοχεα nmda και χρησεις αυτων - Google Patents

Ετεροαρωματικοι ρυθμιστες υποδοχεα nmda και χρησεις αυτων

Info

Publication number
CY1126144T1
CY1126144T1 CY20231100387T CY231100387T CY1126144T1 CY 1126144 T1 CY1126144 T1 CY 1126144T1 CY 20231100387 T CY20231100387 T CY 20231100387T CY 231100387 T CY231100387 T CY 231100387T CY 1126144 T1 CY1126144 T1 CY 1126144T1
Authority
CY
Cyprus
Prior art keywords
heteroaromatic
nmda receptor
receptor regulators
regulators
methylazetidin
Prior art date
Application number
CY20231100387T
Other languages
English (en)
Inventor
Robert A. Volkmann
David R Anderson
Sam Malekiani
Timothy Piser
Gregg F. Keaney
Steven C. LEISER
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1126144T1 publication Critical patent/CY1126144T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Παρέχεται 5-(3-χλωρο-4-φθοροφαινυλο)-7-κυκλοπροπυλο-3-(2-(3-φθορο-3-μεθυλαζετιδιν-1 -υλ)-2-οξοαιθυλο)-3,7-διϋδρο-4Η-πυρρολο[2,3-d]πυριμιδιν-4-όνη και φαρμακευτικώς αποδεκτά άλατα αυτής, και οι χρήσεις τους στη θεραπεία ψυχιατρικών, νευρολογικών, και νευροαναπτυξιακών διαταραχών, όπως επίσης κι ασθενειών του κεντρικού νευρικού συστήματος.
CY20231100387T 2018-08-03 2023-08-02 Ετεροαρωματικοι ρυθμιστες υποδοχεα nmda και χρησεις αυτων CY1126144T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714100P 2018-08-03 2018-08-03
PCT/US2019/044814 WO2020086136A2 (en) 2018-08-03 2019-08-02 Heteroaromatic nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
CY1126144T1 true CY1126144T1 (el) 2023-11-15

Family

ID=69228330

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20231100387T CY1126144T1 (el) 2018-08-03 2023-08-02 Ετεροαρωματικοι ρυθμιστες υποδοχεα nmda και χρησεις αυτων

Country Status (37)

Country Link
US (4) US10584131B2 (el)
EP (2) EP3830092B1 (el)
JP (1) JP7319369B2 (el)
KR (1) KR20210039432A (el)
CN (1) CN112513047B (el)
AR (1) AR115905A1 (el)
AU (1) AU2019368147B2 (el)
BR (1) BR112021001967A2 (el)
CA (1) CA3108519A1 (el)
CL (1) CL2021000294A1 (el)
CO (1) CO2021002898A2 (el)
CR (1) CR20210125A (el)
CU (1) CU24647B1 (el)
CY (1) CY1126144T1 (el)
DK (1) DK3830092T3 (el)
DO (1) DOP2021000025A (el)
EA (1) EA202190431A1 (el)
EC (1) ECSP21014902A (el)
ES (1) ES2951872T3 (el)
FI (1) FI3830092T3 (el)
HR (1) HRP20230774T1 (el)
HU (1) HUE062566T2 (el)
IL (1) IL280474B2 (el)
JO (1) JOP20210020A1 (el)
LT (1) LT3830092T (el)
MA (1) MA53351B1 (el)
MX (1) MX2021001367A (el)
PE (1) PE20210948A1 (el)
PH (1) PH12021550242A1 (el)
PL (1) PL3830092T3 (el)
PT (1) PT3830092T (el)
RS (1) RS64359B1 (el)
SG (1) SG11202101125VA (el)
SI (1) SI3830092T1 (el)
TW (1) TWI833783B (el)
WO (1) WO2020086136A2 (el)
ZA (1) ZA202101273B (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3386591B1 (en) * 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2358891A1 (fr) 1976-07-22 1978-02-17 Yamanouchi Pharma Co Ltd Composes heterocycliques contenant un azote, utilise comme agents analgesiques et anti-inflammatoires
FR2549834B1 (fr) 1983-07-25 1985-10-18 Sanofi Sa Derives de triazolo-pyrimidine, leur procede de preparation et leur application therapeutique en tant que tonicardiaques
US4921854A (en) 1986-12-30 1990-05-01 Egis Gyogyszergyar Condensed thiazolopyrimidine, pyrimido-thiazine or thiazepine pyrimidine compounds
US5298502A (en) 1988-12-12 1994-03-29 Fmc Corporation Method and composition for photodynamic treatment and detection of tumors
WO1994027975A1 (de) 1993-05-21 1994-12-08 Pentapharm Ag 3-(mercaptoalkyl)- bzw. 3-(alkylthioalkyl)-pyrimidin-2,4 (1h, 3h)-dione
AU719102B2 (en) 1996-06-28 2000-05-04 Merck & Co., Inc. Fibrinogen receptor antagonist prodrugs
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives
EP1296958A4 (en) 2000-06-26 2004-01-28 Merck & Co Inc ANTIAGONISTS OF NMDA NR2B RECEPTORS OF IMINOPYRIMIDINE
US6878743B2 (en) 2001-09-18 2005-04-12 Sunesis Pharmaceuticals, Inc. Small molecule inhibitors of caspases
AR038118A1 (es) 2002-01-14 2004-12-29 Upjohn Co Compuestos derivados de la bencinamida del acido 7-oxo-4,7-dihidrotien[2,3-b[piridin-6-carboxilico 3-sustituido que son utiles como antivirales
US7005432B2 (en) 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
BRPI0513379A (pt) 2004-07-13 2008-05-06 Hoffmann La Roche derivados de sulfonamida
TW200643015A (en) 2005-03-11 2006-12-16 Akzo Nobel Nv 2-(4-oxo-4H-quinazolin-3-yl)acetamide derivatives
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
JP5271909B2 (ja) 2006-09-11 2013-08-21 エム・エス・ディー・オス・ベー・フェー ２−（１−オキソ−１ｈ−イソキノリン−２−イル）アセトアミド誘導体
RU2009113612A (ru) 2006-09-11 2010-10-20 Н.В. Органон (Nl) Ацетамидные производные хиназолинона и изохинолинона
ES2699585T3 (es) 2006-12-15 2019-02-11 Nantbio Inc Derivados de triazina y sus aplicaciones terapéuticas
EP1939187A1 (en) 2006-12-20 2008-07-02 Sanofi-Aventis Substituted heteroaryl pyridopyrimidone derivatives
CA2677296A1 (en) 2007-02-08 2008-08-14 Merck & Co., Inc. Therapeutic agents
JP5675341B2 (ja) 2007-04-18 2015-02-25 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオキソキナゾリノン誘導体
CA2685753A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
US8653059B2 (en) 2007-08-21 2014-02-18 Merck Sharp & Dohme Corp. Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AU2009243006B2 (en) 2008-05-01 2013-03-21 Sirtris Pharmaceuticals, Inc. Quinolines and related analogs as sirtuin modulators
US20110077248A1 (en) 2008-05-29 2011-03-31 Sirtris Pharmaceuticals, Inc. Imidazopyridine and related analogs as sirtuin modulators
EP2138494A1 (en) 2008-06-26 2009-12-30 Sanofi-Aventis Substituted alkyl pyrimidin-4-one derivatives
KR20110036602A (ko) 2008-07-03 2011-04-07 서트리스 파마슈티컬즈, 인코포레이티드 시르투인 조절제로서의 벤즈이미다졸 및 관련 유사체
CN101628913B (zh) 2008-07-18 2013-01-23 中国科学院广州生物医药与健康研究院 用作雌激素相关受体调节剂的化合物及其应用
AU2009295948B2 (en) 2008-09-29 2013-12-05 GlaxoSmithKline, LLC Quinazolinone, quinolone and related analogs as sirtuin modulators
PE20142099A1 (es) 2009-01-12 2014-12-13 Icagen Inc Derivados de sulfonamida
EP2411370B1 (en) 2009-03-27 2015-04-22 AbbVie Inc. Compounds as cannabinoid receptor ligands
EP2264035A1 (en) 2009-06-04 2010-12-22 Merz Pharma GmbH & Co. KGaA Glycine B antagonists
TW201116532A (en) 2009-08-05 2011-05-16 Merz Pharma Gmbh & Co Kgaa Metabotropic glutamate receptor modulators
JP2013507417A (ja) 2009-10-13 2013-03-04 エム・エス・ディー・オス・ベー・フェー アセチルコリン受容体に関連する疾患の処置のための縮合アジン誘導体
EP2552907B1 (en) 2010-03-26 2014-10-22 Boehringer Ingelheim International GmbH Pyridyltriazoles
EP2552905B1 (en) 2010-03-26 2016-10-05 Boehringer Ingelheim International GmbH B-Raf kinase inhibitors
WO2012009688A1 (en) 2010-07-16 2012-01-19 Rockefeller University Organic compounds
US9394290B2 (en) 2010-10-21 2016-07-19 Universitaet Des Saarlandes Campus Saarbruecken Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases
US20120165330A1 (en) 2010-12-22 2012-06-28 Sirtris Pharmaceuticals, Inc. Quinazolinone and related analogs as sirtuin modulators
US9464065B2 (en) 2011-03-24 2016-10-11 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
BR112013028886A2 (pt) 2011-05-10 2016-08-09 Gilead Sciences Inc compostos heterocíclicos fundidos como moduladores dde canal de sódio
US9493412B2 (en) 2011-09-27 2016-11-15 Bristol-Myers Squibb Company Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors
WO2013048942A1 (en) 2011-09-30 2013-04-04 Bristol-Myers Squibb Company Quinolinone carboxamide inhibitors of endothelial lipase
EP2760839B1 (en) 2011-09-30 2015-11-25 Bristol-Myers Squibb Company Pyridinedione carboxamide inhibitors of endothelial lipase
CN102336768A (zh) 2011-10-24 2012-02-01 中国科学院上海有机化学研究所 N’-芳亚甲基-2-(4-氧代噻吩[2,3-d]嘧啶-3-基)乙酰腙类化合物、制备方法和用途
PL3628320T3 (pl) 2011-11-11 2022-07-25 Gilead Apollo, Llc Inhibitory acc i ich zastosowania
PE20142364A1 (es) 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
WO2014066743A1 (en) 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014179144A1 (en) 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
US9670203B2 (en) 2013-06-28 2017-06-06 Beigene, Ltd. Fused tricyclic urea compounds as Raf kinase and/or Raf kinase dimer inhibitors
WO2015007453A1 (en) 2013-07-15 2015-01-22 Syngenta Participations Ag Microbiocidal heterobicyclic derivatives
TW201609656A (zh) 2013-09-26 2016-03-16 美涅莫辛製藥公司 Ｎｒ２ａ之ｎ-芳基甲基磺醯胺負向調節劑
CA2926830C (en) 2013-10-11 2023-08-01 F. Hoffmann-La Roche Ag Thiazolopyrimidinones as modulators of nmda receptor activity
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
CN103664877A (zh) 2013-12-25 2014-03-26 重庆医药工业研究院有限责任公司 一种喹啉衍生物、其制备方法和应用
US9617226B2 (en) 2014-09-05 2017-04-11 AbbVie Deutschland GmbH & Co. KG Fused heterocyclic or carbocyclic compounds carrying a substituted cycloaliphatic radical and use thereof for treating vasopressin-related diseases
US12006328B2 (en) 2014-11-18 2024-06-11 Emory University Thieno[2,3-d]pyrimidin-4-one derivatives as NMDAR modulators and uses related thereto
CR20170462A (es) 2015-04-15 2018-02-01 Hoffmann La Roche Piridopirimidinonas y utilización de las mismas como moduladores de receptores nmda
AU2016340080A1 (en) 2015-10-16 2018-05-10 Northwestern University Pharmaceutical combination of an atypical antipsychotic and an NMDA modulator for the treatment of schizophrenia,bipolar disorder, cognitive impairment and major depressive disorder
EP4219507A3 (en) 2015-12-09 2023-08-16 Novartis AG Thienopyrimidinone nmda receptor modulators and uses thereof
EP3386591B1 (en) 2015-12-09 2020-06-24 Cadent Therapeutics, Inc. Heteroaromatic nmda receptor modulators and uses thereof
US20170305861A1 (en) 2016-04-25 2017-10-26 Immunomet Therapeutics, Inc Heteroaryl compounds comprising nitrogen and use thereof
US11186564B2 (en) 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
US11274107B2 (en) 2016-12-22 2022-03-15 Cadent Therapeutics, Inc. NMDA receptor modulators and uses thereof
EP3988552A1 (en) 2017-09-27 2022-04-27 Incyte Corporation Salts of pyrrolotriazine derivatives useful as tam inhibitors
EA202190431A1 (ru) 2018-08-03 2021-06-11 Кэйдент Терапьютикс, Инк. Гетероароматические модуляторы nmda рецептора и их применение
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor

Also Published As

Publication number Publication date
HUE062566T2 (hu) 2023-11-28
CU24647B1 (es) 2023-02-13
SI3830092T1 (sl) 2023-09-29
EP3830092A2 (en) 2021-06-09
PE20210948A1 (es) 2021-05-24
ZA202101273B (en) 2023-05-31
ES2951872T3 (es) 2023-10-25
FI3830092T3 (fi) 2023-07-21
DK3830092T3 (en) 2023-08-07
EA202190431A1 (ru) 2021-06-11
CA3108519A1 (en) 2020-04-30
CO2021002898A2 (es) 2021-05-31
US20240199617A1 (en) 2024-06-20
EP3830092B1 (en) 2023-05-03
US20210403474A1 (en) 2021-12-30
US10584131B2 (en) 2020-03-10
US11542264B2 (en) 2023-01-03
SG11202101125VA (en) 2021-03-30
AU2019368147A1 (en) 2021-03-18
DOP2021000025A (es) 2021-05-31
MA53351B1 (fr) 2023-08-31
PL3830092T3 (pl) 2023-11-13
MA53351A (fr) 2022-01-12
AU2019368147B2 (en) 2024-05-30
PH12021550242A1 (en) 2021-11-29
US20200039987A1 (en) 2020-02-06
PT3830092T (pt) 2023-07-25
AR115905A1 (es) 2021-03-10
RS64359B1 (sr) 2023-08-31
HRP20230774T1 (hr) 2023-10-27
MX2021001367A (es) 2021-06-23
BR112021001967A2 (pt) 2021-04-27
TWI833783B (zh) 2024-03-01
JP2021534227A (ja) 2021-12-09
WO2020086136A2 (en) 2020-04-30
CN112513047B (zh) 2023-10-20
IL280474B1 (en) 2023-05-01
IL280474B2 (en) 2023-09-01
CU20210013A7 (es) 2021-09-07
US20200131190A1 (en) 2020-04-30
KR20210039432A (ko) 2021-04-09
IL280474A (en) 2021-03-01
TW202019932A (zh) 2020-06-01
JP7319369B2 (ja) 2023-08-01
WO2020086136A3 (en) 2020-08-06
CR20210125A (es) 2021-06-30
US10752633B2 (en) 2020-08-25
EP4223760A1 (en) 2023-08-09
CN112513047A (zh) 2021-03-16
ECSP21014902A (es) 2021-05-31
JOP20210020A1 (ar) 2021-01-25
LT3830092T (lt) 2023-09-11
CL2021000294A1 (es) 2021-06-18

Similar Documents

Publication Publication Date Title
CY1126144T1 (el) Ετεροαρωματικοι ρυθμιστες υποδοχεα nmda και χρησεις αυτων
PH12018500087A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
CO2019013707A2 (es) Polinucleótidos de aadc para el tratamiento de la enfermedad de parkinson
MX2019008690A (es) Compuestos espiro heterociclicos como inhibidores de magl.
PA8597301A1 (es) Derivados de imidazol-4-il-etinil-piridina
EA201791239A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
GEP20227446B (en) New catecholamine prodrugs for use in treatment of parkinson's disease
CY1118848T1 (el) Ενωσεις 1,3-οξαζολιδινης ή 1,3-οξαζινανης ως ανταγωνιστες υποδοχεα ορεξινης
CY1118021T1 (el) Παραγωγο αζολιου
CY1124574T1 (el) Προφαρμακο παραγωγου αμινοξεος
ECSP056202A (es) Derivados de imidazol como antagonistas del receptor del glutamato
MX2019008626A (es) Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
PH12016501651B1 (en) Triazine compound and use thereof for medical purposes
CY1111032T1 (el) Παραγωγα τετραλινης και ινδανιου και οι χρησεις αυτων
EP4249071A3 (en) Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase
TN2019000175A1 (en) Benzenesulfonamide compounds and their use as therapeutic agents
BR112018005589A2 (pt) “composto, composição farmaceuticamente aceitável, e, uso de um composto”
PH12014502178A1 (en) Fused azole derivative
CR10014A (es) Derivados de 3-alquilazetidina sustituidos con heterociclos.
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
MX2021004085A (es) El uso de un agonista inverso de h3r para el tratamiento de la somnolencia diurna excesiva asociada con la enfermedad de parkinson (ep).
CY1124158T1 (el) Υποκατεστημενο παραγωγο βενζιμιδαζολιου ως ρυθμιστης της δραστικοτητας του tnf
MX2017012677A (es) Uso de derivados de esteres de 1,4-di-n-oxido de quinoxalina para el tratamiento de la giardiasis como agentes anti-giardia-lamblia.
EA201892724A1 (ru) ТЕТРАГИДРОПИРИДО[3,4-b]ИНДОЛОВЫЕ МОДУЛЯТОРЫ ЭСТРОГЕНОВЫХ РЕЦЕПТОРОВ И ИХ ПРИМЕНЕНИЕ